LONDON--(BUSINESS WIRE)--Regulatory News:
Stallergenes Greer plc (the “Company”)(Euronext Paris:STAGR)(Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Tibor Nemes as Global Head of Technical Operations.
Tibor has 20 years of Operations experience in the biotech and pharmaceutical industry in both Europe and in the United States with a proven track record of leadership in engineering, process development and the manufacturing of biologics, solids, and sterile dosage forms. Since 2008, he held roles of increasing responsibility at Novartis most recently heading Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.
Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer, said:
“I am delighted to welcome Tibor as our Global Head of Technical Operations. Given his background and the recent challenges at our Antony site, the timing of his arrival at Stallergenes Greer is ideal. In this new role, Tibor will lead our Technical Operations organization, craft our global manufacturing strategy, and ensure our teams execute to the highest standards of operational excellence. He will play a vital role in helping our Company become the leading biopharmaceutical company focused on enabling people with allergies to live normal lives.”
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market
Additional information is available at http://www.stallergenesgreer.com
This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.